HRP20151447T1 - Kruti pripravak koji sadrži pioglitazon, glimepirid i ester masne kiseline polioksietilen-sorbitana - Google Patents

Kruti pripravak koji sadrži pioglitazon, glimepirid i ester masne kiseline polioksietilen-sorbitana Download PDF

Info

Publication number
HRP20151447T1
HRP20151447T1 HRP20151447TT HRP20151447T HRP20151447T1 HR P20151447 T1 HRP20151447 T1 HR P20151447T1 HR P20151447T T HRP20151447T T HR P20151447TT HR P20151447 T HRP20151447 T HR P20151447T HR P20151447 T1 HRP20151447 T1 HR P20151447T1
Authority
HR
Croatia
Prior art keywords
solid preparation
pioglitazone
fatty acid
sorbitan fatty
glimepiride
Prior art date
Application number
HRP20151447TT
Other languages
English (en)
Inventor
Kazuhiro Doken
Tetsuya Kawano
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34543966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20151447T1 publication Critical patent/HRP20151447T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (4)

1. Kruti pripravak, naznačen time, da obuhvaća jedan sloj koji sadrži pioglitazon ili njegovu sol i jedan sloj koji sadrži glimepirid i ester masne kiseline polioksietilen-sorbitana, koji uključuje Polysorbat 20, Polysorbat 40, Polysorbat 60, Polysorbat 65 i Polysorbat 80 ili mješavinu od dva ili više navedenih estera masne kiseline polioksietilen-sorbitana.
2. Kruti pripravak prema zahtjevu 1, naznačen time, da pioglitazon ili njegova sol je pioglitazon hidroklorid.
3. Kruti pripravak prema zahtjevu 1, naznačen time, da ester masne kiseline polioksietilen-sorbitana je Polysorbat 80.
4. Kruti pripravak prema zahtjevu 1, naznačen time, da obuhvaća jedan sloj koji sadrži pioglitazon hidroklorid i jedan sloj koji sadrži glimepirid i Polysorbat 80.
HRP20151447TT 2003-10-31 2015-12-31 Kruti pripravak koji sadrži pioglitazon, glimepirid i ester masne kiseline polioksietilen-sorbitana HRP20151447T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003371679 2003-10-31
EP04793070.6A EP1677792B1 (en) 2003-10-31 2004-10-21 Solid preparation comprising pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
PCT/JP2004/015958 WO2005041962A1 (en) 2003-10-31 2004-10-21 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester

Publications (1)

Publication Number Publication Date
HRP20151447T1 true HRP20151447T1 (hr) 2016-02-12

Family

ID=34543966

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151447TT HRP20151447T1 (hr) 2003-10-31 2015-12-31 Kruti pripravak koji sadrži pioglitazon, glimepirid i ester masne kiseline polioksietilen-sorbitana

Country Status (28)

Country Link
US (1) US7700128B2 (hr)
EP (1) EP1677792B1 (hr)
KR (2) KR20100012105A (hr)
CN (1) CN1874774B (hr)
AR (1) AR046210A1 (hr)
AU (1) AU2004285354B2 (hr)
BR (1) BRPI0414979A (hr)
CA (1) CA2540225C (hr)
CY (1) CY1117176T1 (hr)
DK (1) DK1677792T3 (hr)
ES (1) ES2556244T3 (hr)
GE (1) GEP20084570B (hr)
HR (1) HRP20151447T1 (hr)
HU (1) HUE028576T2 (hr)
IL (1) IL174201A (hr)
JO (1) JO3106B1 (hr)
MA (1) MA28116A1 (hr)
MX (1) MXPA06004639A (hr)
NO (1) NO340294B1 (hr)
NZ (1) NZ546337A (hr)
PE (1) PE20050923A1 (hr)
PL (1) PL1677792T3 (hr)
PT (1) PT1677792E (hr)
RU (1) RU2359661C2 (hr)
SI (1) SI1677792T1 (hr)
TW (1) TWI339586B (hr)
WO (1) WO2005041962A1 (hr)
ZA (1) ZA200602056B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
TWI384985B (zh) * 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN101478966B (zh) 2006-06-27 2013-08-21 第一三共株式会社 压缩制剂
BRPI0807453B8 (pt) * 2007-02-01 2021-05-25 Takeda Pharmaceuticals Co preparação sólida
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
WO2010076655A1 (en) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarkers for adipose tissue activity
EP2382475A2 (en) 2009-01-07 2011-11-02 IKFE GmbH Biomarkers for appetite regulation
US8623345B2 (en) * 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
WO2013034174A1 (en) * 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
CN104288161A (zh) * 2014-09-19 2015-01-21 四川海思科制药有限公司 一种含吡格列酮格列美脲的药物组合物
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865213A (ja) * 1981-10-13 1983-04-18 Tokai Kapuseru Kk ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
PT726761E (pt) 1993-11-03 2001-07-31 Isomed Inc Composicoes farmaceuticas que microparticulas na forma de micelios
HU212428B (en) * 1994-05-13 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process to prepare pharmaceutical compositions containing gemfibrozyl
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AP1600A (en) * 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
BR9915285A (pt) 1998-11-12 2001-08-07 Smithkline Beecham Plc Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1552832A1 (en) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation

Also Published As

Publication number Publication date
NO340294B1 (no) 2017-03-27
HUE028576T2 (en) 2016-12-28
PE20050923A1 (es) 2005-12-26
ES2556244T3 (es) 2016-01-14
JO3106B1 (ar) 2017-09-20
AU2004285354A1 (en) 2005-05-12
IL174201A0 (en) 2006-08-01
NZ546337A (en) 2009-03-31
ZA200602056B (en) 2007-05-30
KR20060061383A (ko) 2006-06-07
IL174201A (en) 2011-04-28
PL1677792T3 (pl) 2016-05-31
AR046210A1 (es) 2005-11-30
CA2540225C (en) 2012-03-06
BRPI0414979A (pt) 2006-11-21
US20060223870A1 (en) 2006-10-05
NO20062515L (no) 2006-07-31
EP1677792A1 (en) 2006-07-12
MXPA06004639A (es) 2006-06-27
WO2005041962A1 (en) 2005-05-12
MA28116A1 (fr) 2006-08-01
GEP20084570B (en) 2008-12-25
RU2006118786A (ru) 2007-12-10
DK1677792T3 (en) 2015-12-14
TW200524641A (en) 2005-08-01
CY1117176T1 (el) 2017-04-05
AU2004285354B2 (en) 2009-09-17
KR100952090B1 (ko) 2010-04-13
PT1677792E (pt) 2016-02-09
KR20100012105A (ko) 2010-02-05
CN1874774B (zh) 2011-04-13
EP1677792B1 (en) 2015-11-18
RU2359661C2 (ru) 2009-06-27
CN1874774A (zh) 2006-12-06
US7700128B2 (en) 2010-04-20
TWI339586B (en) 2011-04-01
SI1677792T1 (sl) 2016-02-29
CA2540225A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
HRP20151447T1 (hr) Kruti pripravak koji sadrži pioglitazon, glimepirid i ester masne kiseline polioksietilen-sorbitana
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
DK1773312T3 (da) Sammensætning omfattende statiner og omega-3-fedtsyrer
EE05450B1 (et) 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
FR2804016B1 (fr) Nanoemulsion contenant des lipides amphiphiles et un ester de peg et utilisations
HUP0303817A3 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
HUP0401963A3 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
DK1399153T3 (da) Farmaceutisk præparat indeholdende orlistat og en fedtsyre eller et salt deraf
FR2891459B1 (fr) Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
SI1592416T1 (sl) Maščobne kisline s srednjo dolžino verige, gliceridi in analogi kot stimulatorji eritropoeze
IL182763A (en) Indol-3-ylidene-hydrazino-biphenyl- carboxylic acid derivatives and pharmaceutical compositions comprising them for modulating thrombopoietin activity
WO2003062191A8 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
FR2838648B1 (fr) Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
DE602005015486D1 (de) Esterderivate von ascorbinsäure und 2-ketosäuresacchariden
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
IL179336A0 (en) Benzoic acid derivatives and pharmaceutical compositions containing the same
ATE356622T1 (de) Einen lipase-inhibitor und einen saccharosefettsäuremonoester enthaltende pharmazeutische zusammensetzung
IL174248A0 (en) Alkyl carboxylic acid derivatives and pharmaceutical compositions containing the same
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
DE602004022034D1 (de) Herstellung von konjugierten linolsäuren und linolsäuresalzen
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
ATE439362T1 (de) Ester in position 20 von camptothecinen
GB0312147D0 (en) A composition of lactic acid esters of mono- and diglycerides of fatty acids, an emulsifier containing the same and its use
FR2834900B1 (fr) Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications